Research and development of health- and environmentally conscious high-performance products and new markets
First written in FY2016. 24 of 31 entries say "Restated". Latest entry: FY2026.
3 other companies' latest entry also says "Other".
- FY2026Lower R&D spending and allocation to priority areasAnnual report
「In R&D activities during the fiscal year under review, the first year of the implementation phase of the Long-Term Management Vision NSK2030, Medium-Term Management Plan 2027, the company focused its research resources on the 3 priority areas of “advancing and diversifying food,” “pre-disease,” and “carbon circulation,” while also exploring co-creation themes originating from customer needs.」
While R&D expenses declined from ¥315 million in the previous fiscal year to ¥228 million, the company specified the allocation of resources to the 3 priority areas of Medium-Term Management Plan 2027 and the exploration of customer-driven co-creation themes. - FY2026-H1Disclosed interim R&D expenses of ¥119 millionAnnual report
「Total R&D expenses for the current interim consolidated accounting period were ¥119 million.」
The company continued R&D activities into health- and environmentally conscious products and products linked to new markets, and disclosed R&D expenses of ¥119 million for the current interim consolidated accounting period. - FY2025AdvancedAnnual report
「R&D expenses for the current fiscal year were ¥315 million.」
R&D expenses increased from ¥231 million in the previous fiscal year to ¥315 million. The company also provided greater detail on development and application expansion involving biomass materials, modified starch, functional carbohydrates, dietary fiber, and cosmetic and pharmaceutical applications. - FY2025-H1RestatedAnnual report
「Total R&D expenses for the current interim consolidated accounting period were ¥195 million.」
The company continued R&D activities into health- and environmentally conscious products and products linked to new markets, and disclosed R&D expenses of ¥195 million for the current interim consolidated accounting period. - FY2024AdvancedAnnual report
「R&D expenses for the current fiscal year were ¥231 million.」
R&D expenses increased from ¥227 million in the previous fiscal year to ¥231 million. The company also provided greater detail on development activities involving biomass materials, modified starch with new textures, novel functional carbohydrates, dietary fiber, and cosmetic and pharmaceutical applications. - FY2024-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter were ¥148 million.」
The company continued R&D activities related to health- and environmentally conscious products and other products, and disclosed R&D expenses of ¥148 million for the cumulative third quarter. - FY2024-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥48 million.」
The company continued R&D into health- and environmentally conscious products and other products, and disclosed R&D expenses of ¥48 million for the cumulative second quarter. - FY2024-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter were ¥46 million.」
The company continued R&D into health- and environmentally conscious products and other products, and disclosed R&D expenses of ¥46 million for the cumulative first quarter. - FY2023Higher R&D expenses and greater specificity in application developmentAnnual report
「R&D expenses for the current fiscal year were ¥227 million.」
R&D expenses increased from ¥192 million in the previous fiscal year to ¥227 million. The company also provided greater detail on development activities involving modified starch, biomass materials, novel functional carbohydrates, dietary fiber, and cosmetic and pharmaceutical applications. - FY2023-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥84 million.」
The company continued R&D activities related to health- and environmentally conscious products and other products, and disclosed R&D expenses of ¥84 million for the cumulative second quarter. - FY2023-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter period were ¥39 million.」
The company continued R&D activities related to health- and environmentally conscious products and other products, and disclosed R&D expenses of ¥39 million for the cumulative first quarter. - FY2022Higher R&D expenses and greater specificity in application development areasAnnual report
「R&D expenses for the current fiscal year were ¥192 million.」
R&D expenses increased from ¥174 million in the previous fiscal year to ¥192 million, while the company provided greater detail on development activities involving modified starch, biomass materials, novel functional carbohydrates, dietary fiber, and cosmetic and pharmaceutical applications. - FY2022-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter were ¥136 million.」
The company continued its R&D activities and disclosed R&D expenses of ¥136 million for the cumulative third quarter. - FY2022-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter were ¥91 million.」
The company continued its R&D activities and disclosed R&D expenses of ¥91 million for the cumulative second quarter. - FY2022-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter were ¥43 million.」
The company continued R&D into health- and environmentally conscious products and products linked to new markets, and disclosed R&D expenses of ¥43 million for the cumulative first quarter. - FY2021RestatedAnnual report
「In product development, which we are actively pursuing, we will focus on health-oriented and environmentally friendly products, pursue these initiatives including collaboration with external parties, and strive to continue providing products that enhance value for customers.」
The company continues to develop health-oriented and environmentally friendly products, including through collaboration with external parties. R&D expenses were ¥174 million. - FY2021-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter period were ¥122 million.」
The company continues R&D into health-oriented and environmentally friendly products and areas linked to new markets, and disclosed R&D expenses of ¥122 million for the cumulative third quarter period. - FY2021-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter period were ¥79 million.」
The company disclosed R&D expenses of ¥79 million for the cumulative second quarter period. - FY2021-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter period were ¥39 million.」
The company disclosed R&D expenses of ¥39 million for the cumulative first quarter period. - FY2020RestatedAnnual report
「Accordingly, we pursued the development of products that take people’s health and the environment into consideration, as well as efforts to enhance their functionality and value added, and worked to develop new markets by promoting research into uses and applications. In addition, to improve product quality and production efficiency, we actively pursued the development of new products and technologies applying the latest scientific advances, and advanced proposals that could contribute to customers’ product development.」
The company continues to focus its R&D on health and environmental considerations, enhanced functionality and value added, application development, new markets, and improvements in quality and production efficiency. R&D expenses for the fiscal year were ¥174 million. - FY2020-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter period were ¥128 million.」
The company disclosed R&D expenses of ¥128 million for the cumulative third quarter period. - FY2020-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter period were ¥82 million.」
The company disclosed R&D expenses of ¥82 million for the cumulative second quarter period. - FY2020-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter period were ¥40 million.」
The company disclosed R&D expenses of ¥40 million for the cumulative first quarter period. - FY2019RestatedAnnual report
「Accordingly, we pursued the development of products that take people’s health and the environment into consideration, as well as efforts to enhance their functionality and value added, and worked to develop new markets by promoting research into uses and applications. In addition, to improve product quality and production efficiency, we actively pursued the development of new products and technologies applying the latest scientific advances, and advanced proposals that could contribute to customers’ product development.」
The company continues to focus its R&D on health and environmental considerations, enhanced functionality and value added, application development, new markets, and improvements in quality and production efficiency. R&D expenses were ¥198 million. - FY2019-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter period were ¥146 million.」
The company disclosed R&D expenses of ¥146 million for the cumulative third quarter period. - FY2019-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter period were ¥93 million.」
The company disclosed R&D expenses of ¥93 million for the cumulative second quarter period. - FY2019-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter period were ¥49 million.」
The company disclosed R&D expenses of ¥49 million for the cumulative first quarter period. - FY2018RestatedAnnual report
「Accordingly, we pursued the development of products that take people’s health and the environment into consideration, as well as efforts to enhance their functionality and value added, and worked to develop new markets by promoting research into uses and applications. In addition, to improve product quality and production efficiency, we actively pursued the development of new products and technologies applying the latest scientific advances, and advanced proposals that could contribute to customers’ product development.」
The company continues to focus its R&D on health and environmental considerations, enhanced functionality and value added, application development, and improvements in quality and production efficiency. R&D expenses were ¥230 million. - FY2018-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter period were ¥190 million.」
The company disclosed ¥190 million in R&D expenses. - FY2018-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter period were ¥137 million.」
The company disclosed total R&D expenses of ¥137 million for the cumulative second quarter period. - FY2016First statedAnnual report
「Accordingly, we pursued the development of high-performance, high-value-added products that take people’s health and the environment into consideration, as well as research to enhance their functionality and develop applications. We also worked to develop new markets by promoting research into uses and applications. In addition, to improve product quality and production efficiency, we actively pursued the development of new products and technologies applying the latest scientific advances, and advanced proposals that could contribute to customers’ product development.」
R&D covers health and the environment, enhanced functionality, application development, new markets, and quality and production efficiency.